Incorporating New Prevention and Treatment Strategies Into HIV Care

Review the latest data on FTC/TAF as PrEP and extended-release injectable CAB plus RPV for long-acting treatment of patients with HIV.
W. David Hardy, MD
Anne-Geneviève Marcelin, PharmD, PhD
Kenneth Mayer, MD
Jürgen K. Rockstroh, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 511 KB
Released: January 28, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
ViiV Healthcare

Related Content

Expert-authored CCO slides on the impact of HIV infection on COVID-19 risk and disease severity and the impact of COVID-19 on access to HIV care

W. David Hardy, MD
Program Director
Monica Gandhi, MD, MPH
Released: September 25, 2020

Expert-authored CCO slides on current and future HIV prevention strategies, including FTC/TDF and FTC/TAF PrEP and long-acting injectable PrEP

W. David Hardy, MD
Program Director
Gregory Huhn, MD, MPHTM
Released: September 25, 2020

Short video log from Dr. Jonathan Appelbaum on managing ART and reducing polypharmacy in an older woman with HIV who presents with frailty and multiple other comorbidities

Jonathan Appelbaum, MD, FACP, AAHIVS Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2020 Expired: September 23, 2021

Download free expert-authored slides reviewing a patient case and the relevant data on polypharmacy and drug-drug interactions in older patients with HIV

Jonathan Appelbaum, MD, FACP, AAHIVS Released: September 24, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue